NEALS 2022 poster: Pharmacokinetics and safety of utreloxastat, a novel 15-lipoxygenase inhibitor for the treatment of amyotrophic lateral sclerosis
This poster, presented at NEALS 2022, shows the results of a phase 1 study assessing the pharmacokinetics and safety of utreloxastat in amyotrophic lateral sclerosis (ALS)
Learn more about ALS, a progressive rare neurodegenerative genetic disease Review the patient demographics and study protocol Discover the supporting dose-dependent results of utreloxastat Explore the pharmacokinetic effects and safety results of utreloxastat for ALS
Utreloxastat is an investigational drug currently in development for ALS.
This poster was developed and funded by PTC Therapeutics for NEALS 2022. It is not part of the official program at NEALS 2022.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-ALS-2300003 | February 2023
Close Register here to access the content on the site MED-ALL-CORP-2200029 | December 2022
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our
Privacy Statement and our Terms and Conditions do not apply.
MED-ALL-CORP-2200029 | September 2023
Close COMING SOON
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available,